1. First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis
- Author
-
Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
We describe the first case of bridge therapy in alpha-mannosidosis (AM) in an infant diagnosed at only 5 months of life who underwent enzyme replacement therapy (ERT) in the pre- and peri-transplant phases. Eight ERT infusions were administered before hematopoietic stem cell transplantation (HSCT) and continued for additional 90 days until complete engraftment. The clinical and laboratory data after 3 years post-HSCT show that the early combined intervention may reduce the disease progression and the urine and plasma content of mannosyl-oligosaccharides (OS) monitored by liquid chromatography tandem mass spectrometry (LC–MS/MS). This report highlights that early diagnosis and prompt initiation of such treatments in AM are the best chance to minimize the progression of symptoms.
- Published
- 2023